NCT05091567 2026-03-10IMforteHoffmann-La RochePhase 3 Active not recruiting660 enrolled 23 charts 2 FDA
NCT02421939 2025-12-04A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationAstellas Pharma IncPhase 3 Completed371 enrolled 36 charts 2 FDA
NCT02003222 2025-11-28Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)Phase 3 Active not recruiting488 enrolled 13 charts 2 FDA